Robert G. Perry

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

B. Neuschwander‐Tetri, G. Gores, J. Wayne, 2021, Gastroenterology.

Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity

S. Heymsfield, J. Praestgaard, B. Goodpaster, 2021, JAMA Network Open.

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof‐of‐Concept Study

J. Praestgaard, R. Roubenoff, D. Laurent, 2017, Journal of the American Geriatrics Society.

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults

D. Papanicolaou, Liang‐Kung Chen, J. Praestgaard, 2020, JAMA network open.